eBook published by Bioprocessing international mentioning Lonza as a proactive investor in development of closed platform systems for CAR-T. 
You may also be interested in:
4D-Nucleofector LV
Cocoon® Platform
MODA®
Analytical Development
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
PBPK tablet close up
Article
From Molecule to Medicine: overcoming development challenges with the right CDMO partner
Publication
Systematic Development of a Detergent Toolbox as an Alternative to Triton X-100
In biomanufacturing, detergents are essential for inactivating enveloped viruses during protein...
White paper
Transferring your cell line with confidence
This white paper explores flexible, data-driven strategies that help streamline biologics...
man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough
Article
Partnering for Innovation: Lonza Supports a UK Biotech Developing an Entirely New Modality with...
Epsilogen CEO, Tim Wilson, shares his company’s experience finding the right CDMO partner, willing...
man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough
Article
Lonza’s Expertise and Technical Appetite Help Epsilogen Bring the First IgE Therapeutic into the...
Tim Wilson, CEO of London-based biotech Epsilogen, discusses the company’s journey to develop a...
Article
Q&A: Getting it right first time - the importance of early expression vector design
In this interview, Lonza’s Dr. Peter O’Callaghan (Senior Director, Head of Expression System...
Webinar (on-demand)
Future-proofing gene therapy: scalable AAV solutions and non-viral innovations
As gene therapy moves toward broader commercialization, the pressure to streamline production and...
Technical/Service brief
GS Gene Expression System: reliability today, innovation for tomorrow
Emerging and small biotechs play a critical role in driving scientific innovation, often advancing...
Article
The Evolving Landscape of ADC Analytical Development
Lentivirus modeled above hand
White paper
Xcite®: an optimized transient transfection platform to accelerate your AAV program from gene to...
Unlock the full potential of your AAV program with Xcite®: a proven path from gene to GMP by being...
Lonza Bend Solid Form Services
Webinar (on-demand)
Amorphous Solid Dispersions (ASDs): Pre-clinical to Commercial Capabilities
Is your drug candidate struggling with solubility, slowing down its path to market?...